Celcuity (CELC) Other Non-Current Assets (2017 - 2026)
Celcuity's (CELC) quarterly Other Non-Current Assets came in at $349000.0 in Q4 2025, up 598.0% on a QoQ basis from $50000.0 in Q2 2018.
Celcuity (CELC) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Celcuity (CELC) has 3 years of Other Non-Current Assets data on file, last reported at $349000.0 in Q4 2025.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $349000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $349000.0 (changed N/A YoY) and the FY2025 annual result came in at $349000.0, changed N/A from the prior year.
- Other Non-Current Assets grew to $349000.0 in Q4 2025, from $50000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $349000.0 in Q4 2025 to a low of $349000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | 661,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 661,000.00 |
| Dec 31, 2025 | 349,000.00 |
| Jun 30, 2018 | 50,000.00 |
| Mar 31, 2018 | 50,000.00 |
| Dec 31, 2017 | 50,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Jun 30, 2017 | 50,000.00 |
| Mar 31, 2017 | 50,000.00 |